CN1960742A - 男性更年期障碍改善剂 - Google Patents
男性更年期障碍改善剂 Download PDFInfo
- Publication number
- CN1960742A CN1960742A CNA2005800176205A CN200580017620A CN1960742A CN 1960742 A CN1960742 A CN 1960742A CN A2005800176205 A CNA2005800176205 A CN A2005800176205A CN 200580017620 A CN200580017620 A CN 200580017620A CN 1960742 A CN1960742 A CN 1960742A
- Authority
- CN
- China
- Prior art keywords
- blood
- plant
- codonopsis
- extract
- lancemaside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 86
- 241000756943 Codonopsis Species 0.000 claims abstract description 62
- 239000008280 blood Substances 0.000 claims abstract description 48
- 210000004369 blood Anatomy 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 48
- 229960003604 testosterone Drugs 0.000 claims abstract description 43
- 230000007423 decrease Effects 0.000 claims abstract description 30
- 241000196324 Embryophyta Species 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 239000003112 inhibitor Substances 0.000 claims abstract description 12
- BYBNLTUPSXGVAV-UHFFFAOYSA-N 6-[[8a-[3-[5-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxycarbonyl-8-hydroxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC2C(C(OC3C(C(O)C(O)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(C)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CCC5OC1OC(C(O)=O)C(O)C(O)C1O BYBNLTUPSXGVAV-UHFFFAOYSA-N 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 32
- 206010072742 Late onset hypogonadism syndrome Diseases 0.000 claims description 31
- ZXFNMDBLCLWZIE-UHFFFAOYSA-N asterlingulatoside D Natural products OC1C(O)C(OC2C(C(OC3C(C(O)C(O)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(C)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CCC5OC1OC(CO)C(O)C(O)C1O ZXFNMDBLCLWZIE-UHFFFAOYSA-N 0.000 claims description 30
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 claims description 26
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 claims description 25
- 150000002338 glycosides Chemical class 0.000 claims description 23
- 229930182470 glycoside Natural products 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 230000001430 anti-depressive effect Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 241000283898 Ovis Species 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 229930183580 tangshenoside Natural products 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000000926 separation method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000178343 Butea superba Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 235000002789 Panax ginseng Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010012205 Delayed puberty Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 240000005546 Piper methysticum Species 0.000 description 3
- 235000016787 Piper methysticum Nutrition 0.000 description 3
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229950009829 prasterone sulfate Drugs 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- -1 4-diox Chemical class 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 240000003444 Paullinia cupana Species 0.000 description 2
- 235000000556 Paullinia cupana Nutrition 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000010813 municipal solid waste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 240000002999 Bacopa monnieri Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- 101100223920 Caenorhabditis elegans rha-1 gene Proteins 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 244000071736 Corypha sylvestris Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- 244000292839 Ficus religiosa Species 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101000927268 Hyas araneus Arasin 1 Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000212324 Oenanthe <angiosperm> Species 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006297 Origanum majorana Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- UOZNXVYMTZITGP-UHFFFAOYSA-N Safrazine hydrochloride Chemical compound [Cl-].[NH3+]NC(C)CCC1=CC=C2OCOC2=C1 UOZNXVYMTZITGP-UHFFFAOYSA-N 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229960000638 milnacipran hydrochloride Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
Abstract
本发明提供一种抑制血中睾酮的下降、预防或改善与男性更年期障碍相伴的各种症状等的安全性高的药品或食品。本发明提供含有党参属植物或其提取物的血中睾酮下降抑制剂和男性更年期障碍改善剂。
Description
技术领域
本发明涉及具有抑制血中睾酮下降作用和改善男性更年期障碍作用的药品或食品。
背景技术
据说睾酮对男性生殖器的发育、骨骼和肌肉的发育、性欲和性冲动的亢进、以及脑与精神方面的活力亢进具有影响。已知血中睾酮在受到强烈的应激(stress)时,其浓度下降。血中睾酮下降时,会引起男性更年期障碍和青春期延迟等疾病。
患有男性更年期障碍时,多种症状(例如,沮丧、抑郁、烦躁、焦虑、神经过敏、活力消失、疲劳感、关节炎、肌炎、肌肉力量下降、出汗、发热、睡眠障碍、记忆力下降、注意力下降、体力耗竭感、性欲下降、勃起障碍、射精感消失等)表现强烈。作为确认是否是男性更年期障碍的方法,有通过血液检查测定血中睾酮浓度和调查问卷的方法。男性更年期障碍发病的年龄,据观察主要是40多岁至50多岁的男性,早至20多岁、或晚至60多岁以后的男性,也有出现该症状。男性更年期障碍的发病,被指出与年富力强的男性担负的事业和家庭的各种压力有很大关系,最近,被怀疑为更年期障碍的中老年男性增加。
对于这样的血中睾酮下降和男性更年期障碍,在临床中,使用含有睾酮的雄激素制剂的激素补充疗法已普及,并且已报告了对各种症状的有效性(例如,非专利文献1)。但是,该治疗方法的对象,仅限于在血液检查中睾酮明显地表现出低值、并且没有前列腺疾病的人。其理由是因为,作为副作用,有引起前列腺肥大症和前列腺癌的明显化的可能性。因此,希望针对血中睾酮下降和与男性更年期障碍相伴的各种症状,开发出副作用少、由安全的原材料构成、可以期待预防和缓和的药品或健康食品。
党参属羊乳(Codonopsis lanceolata.)很久以来以消炎、去痰、滋养强身、强精等为目的,被用于民间医药中,特别是在韩国作为药膳饮食使用。另外,也已报告被用于粉末食品和饮料中(例如,参照专利文献1~2)。作为羊乳的药理作用研究和成分研究,已报告了促进精子形成的作用和改善性行为障碍的作用(例如,参照非专利文献2)。
但是,没有报告羊乳及其含有成分具有抑制血中睾酮下降的作用和改善男性更年期障碍的作用。
专利文献1:特开2001-299273号公报
专利文献2:特开2002-218941号公报
非专利文献1:伊藤樹、久末伸一、塚本泰司、男性更年期障害に対する男性ホルモン補充療法、Geriat.Med.42(9):1151-1156,2004
非专利文献2:平成10~12年度創薬等ヒュ一マンサイエンス研究総合研究報告書、第5分野 健康保持增進·予防医薬品の開発に関する研究、86-99,2001
发明内容
本发明的目的是提供一种抑制血中睾酮的下降、预防或改善与男性更年期障碍相伴的各种症状等的安全性高的药品或食品。
本发明人对安全性高的天然原材料进行了各种探索,结果发现党参属植物或其提取物以及该植物中所含有的特定的皂苷(saponin)和苯丙素(phenylpropanoid)类显著地抑制血中睾酮的下降、对男性更年期障碍的各种症状发挥出优异的改善效果,从而完成了本发明。
即,本发明涉及一种含有党参属植物或其提取物的血中睾酮下降抑制剂。
另外,本发明涉及一种含有党参属植物或其提取物的男性更年期障碍改善剂。
另外,本发明涉及一种食品,含有党参属植物或其提取物,附有表示其用于抑制血中睾酮的下降或者预防、治疗、改善或减轻男性更年期障碍的标记。
另外,本发明涉及一种含有选自党参苷(Tangshenoside)类、Lancemaside-A和丁香苷(Syringin)中的1种或2种以上的血中睾酮下降抑制剂。
另外,本发明涉及一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的男性更年期障碍改善剂。
另外,本发明涉及一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的药品。
另外,本发明涉及一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的食品。
另外,本发明涉及党参属植物或其提取物的用于制造血中睾酮下降抑制剂的用途。
另外,本发明涉及党参属植物或其提取物的用于制造男性更年期障碍改善剂的用途。
另外,本发明涉及党参苷类、Lancemaside-A和丁香苷的用于制造血中睾酮下降抑制剂的用途。
另外,本发明涉及党参苷类、Lancemaside-A和丁香苷的用于制造男性更年期障碍改善剂的用途。
另外,本发明涉及一种抑制血中睾酮下降的方法,其特征在于,进行党参属植物或其提取物的给药或摄取。
另外,本发明涉及一种男性更年期障碍的改善方法,其特征在于,进行党参属植物或其提取物的给药或摄取。
另外,本发明涉及一种抑制血中睾酮下降的方法,其特征在于,进行选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的给药或摄取。
另外,本发明涉及一种男性更年期障碍的改善方法,其特征在于,进行选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的给药或摄取。
根据本发明的血中睾酮下降抑制剂和男性更年期障碍改善剂,能够抑制血中睾酮下降,并能够预防、治疗、改善或减轻与男性更年期障碍相伴的各种症状和青春期延迟,而没有前列腺肥大症和前列腺癌的明显化等副作用。
附图说明
图1是表示本发明给药组和对照组中的束缚应激负荷(restraintstress-loaded)小鼠的血中睾酮浓度的变化的图(平均±标准误差)。
具体实施方式
在本发明中,所谓抑制血中睾酮下降,是指抑制由于应激、年龄增长等引起的血中睾酮浓度下降到正常值以下。因此,血中睾酮下降抑制剂对于由血中睾酮下降引起的疾病和症状、例如男性更年期障碍和青春期延迟等的预防和改善是有用的。
在本发明中,所谓男性更年期障碍的改善,是指预防、治疗、改善或减轻由男性更年期障碍引起的各种症状,例如,例如,沮丧、抑郁、烦躁、焦虑、神经过敏、活力消失、疲劳感、关节炎、肌炎、肌肉力量下降、出汗、发热、睡眠障碍、记忆力下降、注意力下降、体力耗竭感、性欲下降、勃起障碍、射精感消失、老化等。此外,上述男性更年期障碍包含与年龄无关而表现出上述各种症状的全部障碍。
作为本发明中的党参属植物,可以举出例如羊乳(Codonopsislanceolata Trautv.)、党参(C.pilosula Nannf.)、林生党参(C.sylvestris)等。其中,优选羊乳(C.lanceolata Trautv.)。
上述党参属植物,可以使用构成植物体的要素的全部或一部分,例如可以使用根、根茎、叶、茎、花、果实、种子、芽等,优选使用根或根茎。
作为党参属植物的提取物,可以举出在常温或加热下对上述党参属植物进行提取或使用索氏提取器(Soxhlet extractor)等提取装置对上述党参属植物进行提取而得到的各种溶剂提取液、其稀释液、浓缩液、提取物、和将它们干燥而得到的干燥物等。
作为用于得到本发明的提取物的提取溶剂,可以使用极性溶剂和非极性溶剂,也可以将它们混合使用。例如,可以举出:水;甲醇、乙醇、1-丙醇、2-丙醇、1-丁醇等醇类;1,4-二噁烷、四氢呋喃、二乙醚等链状和环状醚类;丙酮、甲乙酮等酮类;乙腈等腈类;乙酸甲酯、乙酸乙酯等酯类;聚乙二醇等聚醚类;二氯甲烷、三氯甲烷、四氯化碳等卤化烃类;己烷、环己烷、石油醚等烃类;苯、甲苯等芳香烃类;吡啶类;超临界二氧化碳;和油脂、蜡、其它油等,其中,优选使用极性溶剂,特别是水、乙醇及其混合液。
提取因使用的溶剂而不同,但可以用常用的方法进行。例如,可以如下进行:在将植物体或其干燥物粉碎、破碎或切断后的物质中加入极性溶剂,在0℃~100℃、优选70℃~100℃下,放置5分钟~24小时、优选放置5分钟~1小时。
上述提取物,可以直接使用,也可以将该提取物稀释,适当地利用过滤或离心分离等操作除去不溶物,除去溶剂,浓缩或冷冻干燥后,根据需要制备成粉末或糊状使用。
另外,可以使用液液分配技术(例如,用乙酸乙酯、二乙醚、己烷等非极性溶剂清洗,并用水进行提取)和各种色谱法等精制技术,从上述提取物中除去非活性的夹杂物后使用,在本发明中优选使用这样除去夹杂物后的物质。这些物质可以根据需要、用公知的方法进行脱臭、脱色等处理后使用。
本发明中的党参苷类、Lancemaside-A和丁香苷的化学结构如下,党参苷类包括党参苷I和党参苷II。
[化学式1]
Lancemaside-A 党参苷I
党参苷II 丁香苷
这些都是党参属植物中含有的成分,如后述的实施例2和3所示,用甲醇等醇类对羊乳(Codonopsis lanceolata)进行提取,将提取的提取物通入各种柱色谱,接着,利用高速液相色谱进行分离精制从而得到。在此,Lancemaside-A是初次分离出的新化合物。
此外,在本发明中,上述化合物不限定于这样的方法,也可以通过从其它天然物提取或化学合成而得到。
本发明的党参属植物或其提取物、党参苷类和Lancemaside-A(以下也称为“党参属植物等”),如后述的实施例所示,具有优异的抑制血中睾酮下降的作用,具有改善男性更年期障碍的作用,并且具有高安全性,所以,可以制成能够作为食品和药品使用的血中睾酮下降抑制剂和男性更年期障碍改善剂。
将本发明的党参属植物等作为食品使用时,可以制成:基于预防、改善或减轻与男性更年期障碍相伴的各种症状(例如,沮丧、抑郁、烦躁、焦虑、神经过敏、活力消失、疲劳感、关节炎、肌炎、肌肉力量下降、出汗、发热、睡眠障碍、记忆力下降、注意力下降、体力耗竭感、性欲下降、勃起障碍、射精感消失、老化等)的观念的食品,例如,在制品、包装容器、产品目录和资料等中附有表示其用于上述用途的标记的病人用食品和特定保健用食品等。
作为食品形态,可以是固体食品、膏状或果酱状的半流体食品、凝胶状食品、饮料、茶叶等所有形态,例如,可以举出粉末、胶囊、颗粒、片剂、饮料、袋泡茶等形态。这样的饮料和食品可以按照常用方法进行加工。
在上述食品中,可以加入以往用于改善男性更年期障碍的药用植物,例如具有抗抑郁作用的植物、具有抗焦虑作用的植物、具有抑制血中DHEA-S(Dehydroepiandrosterone sulfate:硫酸脱氢表雄酮)下降作用的植物或它们的提取物。此外,这些植物可以在单体中具有抗抑郁作用、抗焦虑作用、和抑制血中DHEA-S下降作用中任意2种以上的作用。
作为具有抗抑郁作用的植物,例如,可以举出高丽参、刺五加(Siberian ginseng)、贯叶连翘(Saint John’s wort)、达迷草(damiana)、银杏叶、缬草、绿茶、西番莲、啤酒花、春黄菊、黄芩、枣、莲子、醉椒(kavakava)、石榴、橙花、柠檬马鞭草、菩提树、马郁兰、西番莲、香蜂草、茉莉、熏衣草、薄荷、藏红花、可乐果、黄檗、朴树、水芹、紫苏、罗布麻等,优选罗布麻。
作为具有抗焦虑作用的植物,例如,可以举出醉椒根(kawa)、玫瑰、香蒲、假马齿苋(bacopa)、香紫苏、老颧草、缬草、春黄菊、高丽参、刺五加、熏衣草、银杏叶、柠檬马鞭草、藏红花、西番莲、醉椒(kavakava)。
作为具有抑制血中DHEA-S下降作用的植物,例如,可以举出山药、高丽参、瓜拉那(guarana)、朝鲜五味子、达迷草、积雪草(GotuKola)、艳紫铆(sophon)等,优选艳紫铆。
将本发明的党参属植物等作为药品使用时,可以在党参属植物或其提取物、党参苷类、Lancemaside-A或丁香苷中加入药学上允许的载体,制成药品组合物。
本发明的药品的给药方式没有特别限定,可以举出经口给药、直肠给药、经皮给药、注射给药等通常的给药途径,优选经口给药。
该药品可以根据给药途径,使用药学上允许的载体,制备成适当的固体制剂和液体制剂等。
作为用于经口给药的固体制剂,可以举出胶囊剂、片剂、丸剂、锭剂、散剂和颗粒剂等。固体制剂通常可以将本说明书中记载的组合物与至少1种添加剂(例如,结晶纤维素、乳糖或淀粉)混合而制备。该制剂也可以在添加剂以外、还使用硬脂酸镁那样的润滑剂进行制备。在胶囊剂、片剂和丸剂的情况下,还可以进一步使用缓冲剂。片剂和丸剂可以包覆肠溶性膜。
作为用于经口给药的液体制剂,可以举出含有通常用于液体制剂制备的非活性稀释剂、例如水的药学上能够允许的乳剂、溶液、悬浮剂、糖浆剂和酏剂(elixir)。液体制剂可以通过在本发明的植物体和/或提取物中加入添加剂以外,进一步配合例如湿润剂、乳化剂、悬浮剂、调味剂或香味剂而制备。
在上述药品中,可以加入上述的以往用于男性更年期障碍的改善等的药用植物和用于男性更年期障碍的治疗等的药物,例如具有抗抑郁作用的药物、具有抗焦虑作用的药物、和具有抑制血中DHEA-S下降作用的药物,由此,能够更有效地发挥抑制血中睾酮下降的效果和改善男性更年期障碍的效果。
作为具有抗抑郁作用的药物,例如,可以举出盐酸阿米替林等三环类抗抑郁药、盐酸马普替林等四环类抗抑郁药、马来酸氟伏沙明等SSRI、盐酸米那普仑等SNRI、safrazine hydrochloride等MAO抑制剂、盐酸曲唑酮、舒必利。
作为具有抗焦虑作用的药物,例如,可以举出阿普唑仑、依替唑仑、噁唑仑、氯噁唑仑等苯并二氮卓衍生物和坦度螺酮。
作为具有抑制血中DHEA-S下降作用的药物,例如,可以举出DHEA(硫酸脱氢表雄酮)。
作为本发明的优选方式,例如,可以举出如下获得的组合物:在热水中对羊乳(Codonopsis lanceolata)的根加热30分钟~120分钟后,除去不溶解成分,浓缩溶剂,进行干燥,得到提取物,在由上述方法得到的提取物中,加入具有抗抑郁作用的罗布麻和具有抑制血中DHEA-S下降作用的艳紫铆等,再加入通常用于药品和食品的赋形剂或载体。
将本发明的党参属植物等作为药品使用时的给药量,因给药方法和使用目的而不同,在制成固体制剂时,作为党参属植物或其提取物,换算成原生药,通常1次给药0.01~5g、1日给药量0.01~15g,优选1次给药0.1~1g、1日给药量0.1~3g,优选1日给药量0.5~2g;作为Lancemaside-A、党参苷类、丁香苷,通常1次给药0.01~0.5g、1日给药量0.01~1.5g,优选1次给药0.1~1g、1日给药量0.1~0.3g,优选1日给药量0.1~0.2g。
另外,在制成为液体制剂时,就党参属植物或其提取物来说,换算成原生药,作为0.02~10w/v%溶液,可以1日给药1~3次、1次给药1~50mL;就Lancemaside-A、党参苷类、丁香苷来说,作为0.01~0.5w/v%溶液,可以1日给药1~3次、1次给药1~50ml。
以下,通过实施例对本发明进行说明,但本发明不限定于这些实施例。
实施例
实施例1 羊乳提取物的制备
在1.4kg的羊乳(Codonopsis lanceolata)干燥根中加入13L精制水,在90℃以上的热水中加热1小时后,过滤不溶解成分。对得到的热水提取液进行冷冻干燥,得到476g羊乳提取物。
实施例2 党参苷类和丁香苷的提取
将实施例1中得到的476g羊乳提取物通过聚苯乙烯多孔质树脂(DIAION HP-20),用水清洗后,用甲醇进行洗脱。利用以三氯甲烷和甲醇的混合溶液作为洗脱溶剂的硅胶色谱,对该甲醇洗出部分进行分离,得到部分(fraction)1(含有党参苷II和丁香苷)和部分2(含有党参苷I)。部分1由高速液相色谱(分离条件1)进行分离后,进行浓缩,得到党参苷II(50mg)和丁香苷(70mg)。部分2由高速液相色谱(分离条件2)进行分离后,进行浓缩,得到党参苷I(24mg)。分离条件1(党参苷II和丁香苷的高速液相色谱分离条件)
移动相:25%乙腈
流速:8mL/min
检测波长:210nm
柱:YMC-Pack ODS-AQ(内径20mm、长度250mm、粒径5μm,YMC株式会社生产)
柱温:室温
分离条件2(党参苷I的高速液相色谱分离条件)
移动相:18%乙腈
流速:8mL/min
检测波长:210nm
柱:Mightysil RP-18GP(内径20mm、长度250mm、粒径5μm,关东科学株式会社生产)
柱温:室温
实施例3 Lancemaside-A的提取
在1kg的羊乳(Codonopsis lanceolata)干燥根中加入15L精制水,在90℃以上的热水中加热1小时后,过滤不溶解成分。通过对得到的热水提取液进行干燥,得到0.4kg羊乳提取物。将0.4kg羊乳提取物通过聚苯乙烯多孔质树脂(DIAION HP-20),用水和30%甲醇清洗后,用甲醇进行洗脱。利用以三氯甲烷、甲醇和水的混合溶液作为洗脱溶剂的硅胶色谱对该甲醇洗出部分进行分离,利用高速液相色谱(分离条件3)对含有Lancemaside-A的部分进行分离,将含有Lancemaside-A的洗出液通过DIAION HP-20柱,用水清洗后,用甲醇进行洗脱,进行浓缩和冷冻干燥,得到Lancemaside-A(110mg)。将Lancemaside-A的物性表示如下。
分离条件3(Lancemaside-A的高速液相色谱分离条件)
移动相:含有0.1%三氟乙酸的水∶乙腈混合液(72∶28)
流速:9.99mL/min
检测波长:210nm
柱:TSK gel ODS-80TS(内径20mm、长度250mm、粒径5μm,Tosoh株式会社生产)
柱温:25℃
物性
1)性状:白色粉末
2)MS:电喷雾离子化法
正离子:m/z 1213、[M+Na]+,m/z 1229、[M+K]+,
负离子:m/z 1189、[M-H]-
3)13C-NMR(吡啶-d5(pyridine-d5)):
表1
碳 | ppm | 碳 | ppm |
苷元123456789101112131415161718192021222324252627282930 | 38.826.789.139.655.918.533.540.047.037.023.8122.7144.442.136.274.149.641.347.031.036.032.228.217.015.717.627.2176.033.324.8 | Sugar-3GlcU123456Sugar-28Ara12345Rha123456Xyl(inner)12345Xyl′(terminal)12345 | 107.375.478.273.577.9172.993.475.269.565.962.8101.071.972.783.468.518.4106.275.087.169.066.9106.175.678.271.067.4 |
实施例4 抑制血中睾酮浓度下降的试验
使用实施例1中得到的羊乳提取物,利用以下的方法,研究对由老化和应激产生的血中睾酮浓度下降的抑制效果。每日以1g/kg对7个月大的ddY系雄性小鼠(1组10只)进行1次试验物质的经口给药,持续2周。在最后给药日,在试验物质给药1小时后,进行束缚应激负荷。用柔软的金属网包围小鼠的身体,在绝食断水下负荷16小时(17:00~9:00),在负荷刚结束后,测定血中睾酮浓度。差异显著性检验使用Student’t检验。将结果示于图1,与没有施加应激负荷的组相比,应激负荷组的血中睾酮浓度下降,但在进行羊乳提取物给药的组中,观察到血中睾酮浓度下降被明显抑制的效果。该结果与应激负荷组相比,在5%的显著性水平下有显著差异。另外,在进行Lancemaside-A和党参苷I给药的组中同样也观察到了抑制效果。
实施例5 安全性试验
为了确认实施例1中得到的羊乳提取物的安全性,以30ml/kg的给药液体量对5周大的ddY系小鼠(1组雌雄各4只)进行10g/kg和20g/kg的羊乳提取物的一次经口给药,此后6日,观察体重变化和通常状态。在给药次日和第6日,对各组的雌雄各2只进行解剖,用肉眼观察胸腹部脏器。没有观察到由羊乳提取物的给药引起的死亡例,另外,通常状态、体重变化和解剖观察结果都没有发现异常。
实施例6 男性更年期障碍改善试验
对作为出现男性更年期障碍的年龄的40多岁的3名男性,早饭后和晚饭后、每日2次,各服用0.7g试验物质(0.5g羊乳提取物(换算成原生药为1.47g),0.2g糊精、淀粉等赋形剂),服用14日,测定其服用感觉。结果,3名男性在服用前都很少有早晨勃起,这在临床中是男性更年期障碍的判断症状之一,但开始服用试验物质后,从第3~4日起出现早晨勃起,在直到结束服用的期间,确认早晨勃起。
实施例7 制剂处方例
(1)颗粒剂
表2
成分名称 | 处方量(mg/day) |
羊乳提取物 | 500(换算成原生药:1.47g) |
艳紫铆粉末 | 250 |
罗布麻提取物粉末 | 75 |
糊精 | 150 |
结晶纤维素 | 500 |
乳糖 | 500 |
二氧化硅 | 25 |
合计 | 2000 |
(2)液体制剂
表3
成分名称 | 处方量(mg/day) |
羊乳提取物 | 1000(换算成原生药:2.94g) |
刺五加提取物 | 500 |
高丽参提取物 | 100 |
海藻糖 | 3000 |
果糖 | 2000 |
硬化蓖麻油 | 250 |
苯甲酸钠 | 150 |
柠檬酸 | 适量 |
水 | 适量 |
合计 | 50mL |
Claims (17)
1.一种含有党参属植物或其提取物的血中睾酮下降抑制剂。
2.一种含有党参属植物或其提取物的男性更年期障碍改善剂。
3.一种食品,含有党参属植物或其提取物,附有表示其用于抑制血中睾酮的下降或者预防、治疗、改善或减轻男性更年期障碍的标记。
4.如权利要求3所述的食品,其特征在于:
还含有选自具有抗抑郁作用的植物、具有抗焦虑作用的植物和具有抑制血中DHEA-S下降作用的植物中的任1种或2种以上的植物或其提取物。
5.一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的血中睾酮下降抑制剂。
6.一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的男性更年期障碍改善剂。
7.一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的药品。
8.一种含有选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的食品。
9.如权利要求7所述的药品,其特征在于:
还含有选自具有抗抑郁作用的药物、具有抗焦虑作用的药物和具有抑制血中DHEA-S下降作用的药物中的1种或2种以上的药物。
10.党参属植物或其提取物的用于制造血中睾酮下降抑制剂的用途。
11.党参属植物或其提取物的用于制造男性更年期障碍改善剂的用途。
12.党参苷类、Lancemaside-A和丁香苷的用于制造血中睾酮下降抑制剂的用途。
13.党参苷类、Lancemaside-A和丁香苷的用于制造男性更年期障碍改善剂的用途。
14.一种抑制血中睾酮下降的方法,其特征在于,进行党参属植物或其提取物的给药或摄取。
15.一种男性更年期障碍的改善方法,其特征在于,进行党参属植物或其提取物的给药或摄取。
16.一种抑制血中睾酮下降的方法,其特征在于,进行选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的给药或摄取。
17.一种男性更年期障碍的改善方法,其特征在于,进行选自党参苷类、Lancemaside-A和丁香苷中的1种或2种以上的给药或摄取。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004160445 | 2004-05-31 | ||
JP160445/2004 | 2004-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1960742A true CN1960742A (zh) | 2007-05-09 |
Family
ID=35450656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800176205A Pending CN1960742A (zh) | 2004-05-31 | 2005-05-31 | 男性更年期障碍改善剂 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080274213A1 (zh) |
JP (1) | JPWO2005115426A1 (zh) |
CN (1) | CN1960742A (zh) |
CA (1) | CA2569320A1 (zh) |
WO (1) | WO2005115426A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112535226A (zh) * | 2020-11-04 | 2021-03-23 | 南京林业大学 | 朴树及其提取物在银杏相关产品中的应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104116025B (zh) * | 2014-06-19 | 2016-08-31 | 无限极(中国)有限公司 | 党参多糖在制备具有辅助抑制前列腺癌功效的功能食品中的应用 |
CN104337956A (zh) * | 2014-10-15 | 2015-02-11 | 桑秀伶 | 一种用于治疗阳痿的中药组合物 |
SG11202003122XA (en) | 2017-10-19 | 2020-05-28 | Univ Yale | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof |
CN110438079B (zh) * | 2019-09-12 | 2021-01-19 | 深圳华大基因细胞科技有限责任公司 | 一种党参苷ⅰ体外提高nk细胞杀伤活性的用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5933221A (ja) * | 1982-08-19 | 1984-02-23 | Wakunaga Seiyaku Kk | 心因性性行動障害回復剤 |
US6399116B1 (en) * | 2000-04-28 | 2002-06-04 | Rulin Xiu | Rhodiola and used thereof |
JP4312402B2 (ja) * | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
KR20040003401A (ko) * | 2002-07-02 | 2004-01-13 | (주)바이오자임 인터내셔날 | 남성 성기능 장애에 효과적인 기능성 영양보충용 식품 및그의 제조 방법 |
-
2005
- 2005-05-31 CA CA002569320A patent/CA2569320A1/en not_active Abandoned
- 2005-05-31 JP JP2006513998A patent/JPWO2005115426A1/ja active Pending
- 2005-05-31 WO PCT/JP2005/009937 patent/WO2005115426A1/ja active Application Filing
- 2005-05-31 US US11/597,924 patent/US20080274213A1/en not_active Abandoned
- 2005-05-31 CN CNA2005800176205A patent/CN1960742A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112535226A (zh) * | 2020-11-04 | 2021-03-23 | 南京林业大学 | 朴树及其提取物在银杏相关产品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2569320A1 (en) | 2005-12-08 |
US20080274213A1 (en) | 2008-11-06 |
JPWO2005115426A1 (ja) | 2008-03-27 |
WO2005115426A1 (ja) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhat et al. | Tongkat Ali (Eurycoma longifolia Jack): a review on its ethnobotany and pharmacological importance | |
Xiao et al. | Review of the use of botanicals for epilepsy in complementary medical systems—Traditional Chinese Medicine | |
CN1964730A (zh) | 预防和治疗风湿及炎症性疾病的中药复方和相应的制备方法 | |
CN101612362B (zh) | 一种调节血脂、防治心脑血管疾病复方制剂及其制备方法 | |
CN1836687A (zh) | 治疗抑郁症的药物组合物及其制法 | |
CN1853682A (zh) | 用于改善睡眠持续时间和质量的基于植物的食品强化剂 | |
US8623424B2 (en) | Traditional Chinese medicinal compositions for treating depression, formulation thereof, method for preparing the same thereof | |
CN103533948A (zh) | 神经疾病的治疗及记忆力减退改善用生药组合物 | |
CN101711810B (zh) | 一种用于改善睡眠、提高免疫的制剂 | |
CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
CN103442726A (zh) | 改善、治疗和预防胃肠动力障碍性疾病的组合物 | |
CN1960742A (zh) | 男性更年期障碍改善剂 | |
KR101987418B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
Katekhaye et al. | An inside preview of nutritional and pharmacological profile of Celastrus paniculatus | |
US20160000844A1 (en) | A composition for improving joint health, or for preventing and treating rheumatoid arthritis and osteoarthritis | |
KR101060909B1 (ko) | 뇌 신경 세포 보호물질을 포함하는 질경이 추출물을포함하는 조성물 | |
CN103690832A (zh) | 一种治疗病毒性心肌炎的中药组合物 | |
CN102599501B (zh) | 降脂护肝的保健食品红洋胶囊或片剂 | |
KR101167628B1 (ko) | 흑삼을 함유하는 치매 예방 또는 치료 및 인지기능 개선 조성물 | |
KR101438555B1 (ko) | 생약 추출물을 유효성분으로 함유하는 식욕부진 개선용 조성물 | |
KR100522176B1 (ko) | 남성 성기능 개선 조성물 | |
JP2007084559A (ja) | 血中テストステロン低下抑制剤 | |
CN101028305A (zh) | 灵芝孢子制取物及其制备方法 | |
KR100538983B1 (ko) | 생약추출물이 함유된 간기능 개선용 약학 조성물 | |
CN1535717A (zh) | 中药丁香及其提取物在制备减肥药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070509 |